Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 121,474 matching trials from the live ClinicalTrials.gov search.

Filters: Completed Clear all

Conditions: Chronic Pain
Interventions: Music Therapy; Behavioral
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Heart Disease
Interventions: Dexmedetomidine 1mcg/kg Intranasal, Dexmedetomidine 2mcg/kg Intranasal, Dexmedetomidine 1mcg Intravenous; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 6 Months to 48 Months
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Renal Impairment
Interventions: Emraclidine; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 5
States / cities: Tustin, California • Miami, Florida • Orlando, Florida + 1 more

Conditions: Cardiovascular Disease
Interventions: Strawberry Meal, Control Meal; Dietary Supplement
Lead sponsor: Penn State University; Other
Eligibility: 20 Years to 50 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Tirapazamine, Cisplatin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Total Knee Arthroplasty (Postoperative Pain)
Interventions: ATX101, bupivacaine hydrochloride, saline placebo; Drug
Lead sponsor: Allay Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 11
States / cities: Little Rock, Arkansas • Tamarac, Florida • Atlanta, Georgia + 7 more

Conditions: Post Traumatic Stress Disorder
Interventions: Not listed
Lead sponsor: Central Arkansas Veterans Healthcare System; Federal
Eligibility: 18 Years to 60 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: North Little Rock, Arkansas

Conditions: Colorectal Cancer
Interventions: Oral CC-486, Romidepsin, MK-3475; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Lung Cancer
Interventions: gemcitabine hydrochloride, irinotecan hydrochloride; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2008
U.S. locations: 50
States / cities: Birmingham, Alabama • La Jolla, California • San Francisco, California + 31 more

Conditions: Anesthesia, Deep Sedation
Interventions: qCON-qNOX, BIS; Device
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Reinforcing Value of Food
Interventions: Daily snack food intake; Behavioral
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Diabetes, Gestational
Interventions: 1-Self-monitoring of blood glucose, 2-Self-weighing, 3-Self-checking of blood pressure, 4-Checking fetal heart rate, 5-Visits with caregivers; Device · Procedure
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Multiple Sclerosis
Interventions: Teriflunomide, Placebo (for teriflunomide), Interferon-β [IFN-β], Glatiramer Acetate [GA]; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Alzheimer Disease, Early Onset
Interventions: 3TC; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 50 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: San Antonio, Texas

Conditions: Influenza
Interventions: Trivalent inactivated influenza vaccine, Trivalent Baculovirus-expressed Influenza HA vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Respiratory Syncytial Virus Infections
Interventions: GSK3888550A RSV Maternal vaccine formulation 1, GSK3888550A RSV Maternal vaccine formulation 2, GSK3888550A RSV Maternal vaccine formulation 3, Placebo (Normal Saline); Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 502 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Lenexa, Kansas • Rochester, New York

Conditions: Chronic Plantar Fasciitis
Interventions: Corticosteroid injection (CSI) with local anesthetic (LA), Local anesthetic (LA) with Saline injection; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Parkinson Disease
Interventions: Requip PR, Mirapex; Drug
Lead sponsor: Rajesh Pahwa, MD; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: PrEP Adherence Monitoring
Interventions: Truvada; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 50 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: San Francisco, California • Aurora, Colorado

Conditions: Type 2 Diabetes
Interventions: Cognitive behavioral training; Behavioral
Lead sponsor: University of Hawaii; Other
Eligibility: 18 Years to 76 Years
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Hypercholesterolemia
Interventions: MD-0727; Drug
Lead sponsor: Ironwood Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 20
States / cities: Birmingham, Alabama • Los Angeles, California • Walnut Creek, California + 17 more

Conditions: Spinal Cord Injury, Multiple Sclerosis, Muscular Dystrophy, Cerebral Palsy, Spina Bifida, Amputation, Arthritis, Stroke
Interventions: Educational session to promote physical activity, Minimal contact; Other
Lead sponsor: University of Kansas; Other
Eligibility: 18 Years to 65 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Lawrence, Kansas

Conditions: Anaplastic Astrocytoma, Brain Stem Glioma, Childhood Mixed Glioma, Fibrillary Astrocytoma, Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma, Untreated Childhood Anaplastic Astrocytoma, Untreated Childhood Brain Stem Glioma, Untreated Childhood Fibrillary Astrocytoma, Untreated Childhood Giant Cell Glioblastoma, Untreated Childhood Glioblastoma, Untreated Childhood Gliosarcoma
Interventions: 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Pharmacological Study, Temozolomide, Veliparib; Radiation · Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 12
States / cities: Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 8 more

Conditions: Chronic Hepatitis Delta
Interventions: Bulevirtide; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 2
States / cities: New York, New York

Search by objective public record fields.

POP SINGER Pilot Study

Pharmacokinetic Study of Dexmedetomidine After Intra-nasal Dosing in Children

A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function

Effect of Strawberries on Cardiovascular Disease Risk

TRACE: Tirapazamine-Radiation And Cisplatin Evaluation

Phase 2B Study Assessing Pain Relief After Replacement of the Knee

Predicting Treatment Response Using Psychophysiologic Reactivity Measures

A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer

Combination Chemotherapy in Treating Patients With Recurrent or Refractory Small Cell Lung Cancer

Comparison of Two Electroencephalograms (EEG) Monitors in Patients Undergoing General Anesthesia

Food Reinforcement, Weight Status, and Energy Density

The Virtual Visit for Women With Gestational Diabetes

Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis

Pilot Study to Investigate the Safety and Feasibility of AntiRetroviral Therapy for Alzheimer's Disease

Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell Lymphoma

A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women

Infracalcaneal Peppering Injection Technique for Chronic Plantar Fasciitis

Pramipexole Conversion to Ropinirole Controlled Release (CR)

Pre-Exposure Prophylaxis (PrEP) Adherence Monitoring Using Dried Blood Spots

Cognitive Behavioral Intervention in Diabetes Self-Management

Study of Oral MD-0727 Administered to Patients With Primary Hypercholesterolemia

A Randomized Exercise Trial for Wheelchair Users

Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas

Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD)